hVIVO plc 2017 Annual Report and Financial Statements (4306M)
April 27 2018 - 9:00AM
UK Regulatory
TIDMHVO
RNS Number : 4306M
hVIVO plc
27 April 2018
For immediate release 2.00pm: 27 April 2018
HVIVO PLC
("hVIVO" or the "Company")
2017 Annual Report and Financial Statements
hVIVO plc (AIM: HVO), a pioneer of human disease models and an
industry leading clinical development and drug discovery services
business, is pleased to announce that its Annual Report and
Financial Statements for the year ended 31 December 2017 is being
posted to shareholders today.
It will be available on the Company's website
(http://hvivo.com/investors/financial-reports/) from 4.30 pm
today.
For further information please contact:
hVIVO plc
Trevor Phillips (Executive
Chairman) +44 207 756 1300
Fleur Wood (Director, Investor
Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie
Barnfield (Nominated Adviser)
James Black / Michael Burke
(Corporate Broking)
FTI Consulting
Simon Conway / Victoria
Foster Mitchell +44 203 727 1000
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based analytical
platform to accelerate drug discovery and development in
respiratory and infectious diseases. Leveraging human disease
models in flu, RSV and asthma exacerbation, the hVIVO platform
captures disease in motion, illuminating the entire disease life
cycle from healthy to sick and back to health. Based in the UK,
market leader hVIVO has conducted more than 50 clinical studies,
inoculated over 2500 volunteers and has three first-in-class
therapies currently in development with a growing pre-clinical
pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSFKODQBBKDAQB
(END) Dow Jones Newswires
April 27, 2018 09:00 ET (13:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024